Abstract
Potent P2Y 12 receptor inhibitors, i.e. prasugrel and ticagrelor, are first-line drugs in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Randomized trials have shown superior efficacy and safety of these drugs compared to clopidogrel. The ISAR-REACT 5 study comparing the efficacy and safety of prasugrel vs. ticagrelor demonstrated a higher efficacy of prasugrel, without significant differences in the risk of bleeding between these drugs.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call